Your SlideShare is downloading. ×
Forest Labs Clinical Development Profile
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Forest Labs Clinical Development Profile

106
views

Published on

ISR’s report provides a thorough analysis of Forest Laboratories’ R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Forest’s key products. …

ISR’s report provides a thorough analysis of Forest Laboratories’ R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Forest’s key products.

How You Can Use This Report:
Pharmaceutical Companies: Identify the clinical and commercial status of competing compounds and understand how these will affect the launch of similar products.

Service Providers: Learn Forest’s strategic direction and better understand their clinical development pipeline.


For the full report preview, with table of contents, additional sample pages, and ordering information, please visit our website:
http://www.isrreports.com/product/forest-labs-clinical-development-profile/

Published in: Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
106
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. EW PR EV I Forest Labs Clinical Development Profile Info@ISRreports.com ©2014 Industry Standard Research www.ISRreports.com
  • 2. act with confidence Report Overview ISR’s report provides a thorough analysis of Forest Laboratories’ R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Forest’s key products. Methodologies: Data have been compiled through an exhaustive secondary research effort. ISR has utilized company websites, annual reports, clinicaltrials.gov, and government filings along with additional sources to provide clinical trial and key product data. 44 Charts and Graphs Q1, 2014 Publication Date 50 Pages Report Structure: 1. Background and Strategy 2. Financial Condition • Drug sales • Stock performance • • • • 3. R&D Pipeline Overview • • • • • • 4. Clinical Trial Activity (segmented by phase and trial type) Anti-infective Cardiovascular CNS Gastrointestinal Pain Management Respiratory Number of clinical trials Length of clinical trials Projected vs. Actual on-going trial length Enrollment in clinical trials 5. Patents 6. FDA Submissions • Approved drugs • Discontinued drugs 7. Key Product Profiles What you will learn in this report: • Drug sales and company financial condition over the past four years • Number, length, and patient enrollment of clinical trials segmented by phase and trial type • Current R&D pipeline overview • Important aspects of Forest’s key products such as MOA, dosing, and interaction characteristics How you can use this report: • Pharmaceutical Companies: Identify the clinical and commercial status of competing compounds and understand how these will affect the launch of similar products. • For Service Providers: Learn Forest’s strategic direction and better understand their clinical development pipeline. NEXT: Table of Contents and Sample Pages www.ISRreports.com ©2014 | Preview of: Forest Labs Clinical Development Profile 2
  • 3. act with confidence Table of Contents For table of contents and additional sample pages, download the full preview, available on our website: www.isrreports.com/product/forest-labs-clinical-development-profile/ www.ISRreports.com ©2014 | Preview of: Forest Labs Clinical Development Profile 3
  • 4. act with confidence Sample Page Clinical trial activity act with confidence Clinical trial activity Data used in this analysis was pulled from ClinicalTrials�gov (www�clinicaltrials�gov) on 10 December 2013� The analysis includes all trials conducted by Forest Laboratories listed on ClinicalTrials�gov� Data/ clinical trials were segmented into three groups: • Ongoing trials (N=51 trials)—these clinical studies are currently ongoing� • Past 2 years (N=84 trials)—these trials were completed in the past two years� • Historic trials (N=141 trials)—these trials were completed more than two years ago Clinical trial activity and were not analyzed for this report� Clinical trial activity The analyses that follow center on only the 135 clinical trials that are currently ongoing and those that have been completed in the past two years� act with confidence For definitional purposes: act with confidence • An “ongoing” trial is a trial with an ending date after 1 December 2013� • A “recently completed” trial is one with an ending date occurring after 1 December 2011 but before 1 December 2013 (past two years)� The following sections reflect the number of clinical trials that were found in the clinical trials database� The following sections reflect the number of clinical trials that were found in the clinical trials database� Number of clinical trials, by phase Percentages are based on the number of ongoing and Number of clinical trials, (N=135)� recently read the table: 2%two by phase completed (past of years) trials conducted by Forest Laboratories How to the 51 ongoing based on the number of Laboratories are in Phase 1� Percentages aretrials conducted by Forestongoing and recently completed (past two years) trials conducted by Forest Laboratories (N=135)� How to read the table: 2% of the 51 ongoing trials conducted by Forest Laboratories are in Phase 1� Ongoing Recently Total Completed Trials Ongoing Total Phase 1 Total 2 Phase Phase 1 Phase 3 Phase 2 Phase 4 Phase 3 No Phase Phase 4 No Phase 51 1 (2%) 51 9 (18%) 1 (2%) 15 (29%) 9 (37%) 19(18%) 15 (14%) 7 (29%) 19 (37%) 7 (14%) (past two years) Recently Completed Trials 84 (past two years) 3 (4%) 17 84 (20%) 3 (32%) 27 (4%) 17 (20%) 26 (31%) 27 (13%) 11 (32%) 26 (31%) 11 (13%) Total 135 4 (3%) 26135 (19%) 4 (31%) 42 (3%) 26 (19%) 45 (33%) 42 (13%) 18 (31%) 45 (33%) Research © 2014 Industry Standard 18 (13%) www.ISRreports.com ©2014 | Forest Labs Clinical Development Profile © 2014 Industry Standard Research 14 Study type distribution (e�g� interventional) Development Profile www.ISRreports.com ©2014 | Preview of: Forest Labs Clinical This is an enterprise-wide license and this file is not to be distributed beyond the terms of this agreement. For information on the license holder, please contact ISR (info@ISRreports.com). The table the number of ongoing and recently completed StudyrepresentsForest Laboratories by the type of study type listed(past two years) type distribution (e�g� interventional) trials conducted by in 4
  • 5. act with confidence Sample Page: Key Product Profiles For table of contents and additional sample pages, download the full preview, available on our website: www.isrreports.com/product/forest-labs-clinical-development-profile/ www.ISRreports.com ©2014 | Preview of: Forest Labs Clinical Development Profile 5
  • 6. act with confidence Ordering Information For pricing and ordering information, please visit our website: www.isrreports.com/product/forest-labs-clinical-development-profile/ Save on this, or any ISR report, by registering a free account Register now • Receive a $250 instant credit towards any ISR report • Earn 10% credit towards all future purchases • Receive advanced notifications on ISR’s latest reports and free resources About Industry Standard Research Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.    For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www. ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports. www.ISRreports.com ©2014 | Preview of: Forest Labs Clinical Development Profile 6
  • 7. The ISR Difference act with confidence Custom-quality syndicated market research www.ISRreports.com ISR's Reports vs. The Common Syndicated Report How confident are you? Research methods Mostly primary research; always appropriate for the topic vs. vs. One size fits all; usually publically available data Data Collection ISR's proprietary data collection tools and channels support fast, high quality data collection vs. Struggle to recruit the right targets and enough of them Respondents Sophisticated screening ensures genuine decision-makers vs. Undisclosed methodologies and respondent demographics Sample Sizes Robust sample sizes that instill confidence vs. Often insufficient industry representation that leaves you defending results Analysts Decades of experience means more insights that are immediately usable vs. vs. Junior analysts capable of reporting numbers www.ISRreports.com ©2013 | | ©2014 | Preview of: Forest Labs Industry’s HEOR Functions www.ISRreports.com Preview of: Benchmarking European Industry’s HEOR Functions 7 www.ISRreports.com ©2013©2014 Preview of: BenchmarkingPharmaClinical Development Profile 10 www.ISRreports.com | Preview of: Benchmarking the the Pharma Investigator Payments